Cargando…

Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator

BACKGROUND AND OBJECTIVE: Systemic inflammation response index (SIRI=N×M/L), based on neutrophil (N), monocyte (M), and lymphocyte (L) counts, is used to predict the survival of patients with malignant tumors and can fully evaluate the balance between host immune and inflammatory condition. The pres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Li, Kong, Xiangyi, Wang, Zhongzhao, Wang, Xiangyu, Fang, Yi, Wang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060771/ https://www.ncbi.nlm.nih.gov/pubmed/32184659 http://dx.doi.org/10.2147/CMAR.S235519

Ejemplares similares

Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator
por: Chen, Li, et al.
Publicado: (2021)

Pre‐treatment systemic immune‐inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy
por: Chen, Li, et al.
Publicado: (2020)

Nutritional Risk Index Predicts Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy
por: Chen, Li, et al.
Publicado: (2022)

Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Chen, Li, et al.
Publicado: (2022)

NCCBM, a Nomogram Prognostic Model in Breast Cancer Patients With Brain Metastasis
por: Liu, Qiang, et al.
Publicado: (2021)

Peripheral inflammation/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy
por: Qian, Yi, et al.
Publicado: (2018)

Conditional Survival of female patients with operable invasive Breast Cancer in US: A population-based study
por: Ai, Bolun, et al.
Publicado: (2020)

Comparisons of Therapeutic and Aesthetic Effects of One-Stage Implant-Based Breast Reconstruction with and without Biological Matrix
por: Gao, Peng, et al.
Publicado: (2020)

The Systemic Immune-Inflammation Index is an Independent Predictor of Survival in Breast Cancer Patients
por: Zhu, Mengliu, et al.
Publicado: (2022)

Comprehensive Analysis of the Expressionand Prognosis for TDO2 in Breast Cancer
por: Liu, Qiang, et al.
Publicado: (2020)

A Systematic Study on Zinc-Related Metabolism in Breast Cancer
por: Qu, Zheng, et al.
Publicado: (2023)

Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy
por: Dong, Jie, et al.
Publicado: (2021)

The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study
por: Zhu, Mengliu, et al.
Publicado: (2022)

Systemic immune–inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy
por: Chen, Li, et al.
Publicado: (2017)

Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples
por: Liu, Qiang, et al.
Publicado: (2021)

Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy
por: Li, Xinyan, et al.
Publicado: (2019)

In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator
por: Chen, Li, et al.
Publicado: (2021)

Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy
por: Zhang, Wenxiang, et al.
Publicado: (2021)

Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study
por: Chen, Yi, et al.
Publicado: (2016)

Peripheral Blood Cell Ratios as Prognostic Indicators in a Neoadjuvant Chemotherapy-Treated Breast Cancer Cohort
por: Jalali, Amirhossein, et al.
Publicado: (2022)

Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer
por: Li, Jing, et al.
Publicado: (2016)

Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database
por: Cheng, Ran, et al.
Publicado: (2020)

Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data
por: Liu, Qiang, et al.
Publicado: (2020)

Pretreatment Inflammatory Indexes as Prognostic Predictors for Survival in Colorectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy
por: Yang, Jing, et al.
Publicado: (2018)

Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB
por: Liu, Pingping, et al.
Publicado: (2022)

Identification of the Significant Genes Regulated by Estrogen Receptor in Estrogen Receptor-Positive Breast Cancer and Their Expression Pattern Changes When Tamoxifen or Fulvestrant Resistance Occurs
por: Cheng, Ran, et al.
Publicado: (2020)

Prognostic value of systemic inflammation response index in hepatoblastoma patients receiving preoperative neoadjuvant chemotherapy
por: Zheng, Chen, et al.
Publicado: (2023)

Recent advances of transcriptomics and proteomics in triple‐negative breast cancer prognosis assessment
por: Li, Yuan, et al.
Publicado: (2022)

LINC01355 suppresses breast cancer growth through FOXO3-mediated transcriptional repression of CCND1
por: Ai, Bolun, et al.
Publicado: (2019)

Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Chang, Ji Hyun, et al.
Publicado: (2016)

Systemic Immune-Inflammation Index Is Superior to Neutrophil to Lymphocyte Ratio in Prognostic Assessment of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Jiang, Cong, et al.
Publicado: (2020)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
por: Qi, Yihang, et al.
Publicado: (2021)

A prognostic index for locoregional recurrence after neoadjuvant chemotherapy
por: Herrero-Vicent, C, et al.
Publicado: (2016)

Pretreatment glycemic control status is an independent prognostic factor for cervical cancer patients receiving neoadjuvant chemotherapy for locally advanced disease
por: Li, Jing, et al.
Publicado: (2017)

Prognostic Value of the Pretreatment Systemic Immune-Inflammation Index in Patients with Colorectal Cancer
por: Li, Jing, et al.
Publicado: (2020)

Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment
por: Li, Yuan, et al.
Publicado: (2021)

Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Truffi, Marta, et al.
Publicado: (2022)

Subsequent risk of suicide among 9,300,812 cancer survivors in US: A population-based cohort study covering 40 years of data
por: Liu, Qiang, et al.
Publicado: (2022)

Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study
por: Zhu, Wenjie, et al.
Publicado: (2015)

Inflammation and nutritional status indicators as prognostic indicators for patients with locally advanced gastrointestinal stromal tumors treated with neoadjuvant imatinib
por: Ding, Ping’an, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vj8g4ubipqs58fqnodpl5n2b0g